Lupin acquires Hormosan in Germany
This article was originally published in Scrip
Lupinhas acquired the German sales and marketing company Hormosan Pharma, for an undisclosed sum. The acquisition, Lupin's first in Europe, establishes a bridgehead in Germany, through which the Indian company expects to launch a range of products. Lupin's managing director, Dr Kamal Sharma, said that Lupin had never "chased size but only strategic fit" and Hormosan offered just that. "We have made a modest investment. Hormosan is a lean smart machine making modest profits," Dr Sharma said at a press conference in Mumbai.
You may also be interested in...
Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.
High-profile experts including Anthony Fauci and Adrian Hill share views at the ICMR symposium on progressing safe COVID-19 vaccines backed by ethical trials executed with appropriate scientific rigor. Human challenge studies, "vaccine nationalism" and equitable access were among the key issues deliberated, while India committed to making its coronavirus vaccines and related capabilities available to the world.
A Cipla veteran and CEO of the firm’s India business and other executives have quit, though the Indian company maintains it has underlying strength and continued business momentum to sustain growth. ANI Pharmaceuticals in the US has snapped up one outgoing executive as president and CEO.